APSR2026-699

 
Late-Breaking
Submitted
Oral Presentation
AO10-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1221128-46903-APSR2026_Youqian_Zhang_APSR2026-699_439925.pptx
Format: PPTX Only
 
Format: PDF Only
16. Interstitial Lung Disease
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Youqian Zhang * the First Affiliated Hospital of Xi’an Jiaotong University Department of Respiratory and Critical Care Medicine Xi’an China
Chang Liu - the First Affiliated Hospital of Xi’an Jiaotong University Department of Respiratory and Critical Care Medicine Xi’an China
Jiejun Zhou - the First Affiliated Hospital of Xi’an Jiaotong University Department of Respiratory and Critical Care Medicine Xi’an China
Zhenzhen Wang - Xi'an Jiaotong University School of Nursing Xi’an China
Min Peng - Xi'an Jiaotong University School of Nursing Xi’an China
Junxia Ye - Xi'an Jiaotong University School of Nursing Xi’an China
Mingwei Chen - the First Affiliated Hospital of Xi’an Jiaotong University Department of Respiratory and Critical Care Medicine Xi’an China
Tinghua Hu - the First Affiliated Hospital of Xi’an Jiaotong University Department of Respiratory and Critical Care Medicine Xi’an China
 
 
 
 
 
 
 
Presenting Author Details
Youqian
Zhang
zhangyouqian@stu.xjtu.edu.cn
+8618872975134
Under 30
China
Original Research
Genetic Modeling Implicates Intestinal Anti-inflammatory Drug Targets in Idiopathic Pulmonary Fibrosis: Probing Gut Microbiota–Mediated Effects via the Gut–Lung Axis
Maximum 25 words
Abstract Content
Idiopathic pulmonary fibrosis (IPF) has unknown etiology and limited treatments. The gut-lung axis implicates inflammatory bowel disease and anti-inflammatory pathways in its pathogenesis, though mechanisms remain unclear. This study examined causal effects of genes encoding gut anti-inflammatory drug targets on IPF and the mediating role of gut microbiota.
DrugBank and ChEMBL databases were used to identify relevant targets. Cis-expression quantitative trait loci (cis-eQTLs) in lung and blood tissues were obtained from the GTEx and eQTLGen databases as genetic instruments for drug target Mendelian randomization (DTMR) analysis. IPF summary statistics were sourced from FinnGen consortium, with replication in the Global Biobank Meta-analysis Initiative and Million Veteran Program cohorts. Primary analyses employed summary-data-based MR (SMR), inverse-variance-weighted (IVW) and Wald-ratio methods, with false-discovery-rate correction. Two-step mediation analysis using the Delta method evaluated mediation through 473 gut-microbiome traits.
Genetically predicted elevated expression of ALOX5 in lung tissue was associated with increased IPF risk (OR = 2.049, 95% CI: 1.201–3.495, P = 0.008, Padj = 0.037), with replication in whole blood. Supplementary methods, replication analyses, and sensitivity analyses yielded consistent evidence. Two-step mediation analysis revealed that Parabacteroides and Tannerellaceae mediated 7.85% (95% CI: 0.79%–14.91%) and 7.82% (95% CI: 0.58%–15.06%) of the causal effect from ALOX5 to IPF, respectively. Other drug target genes showed no significant causal associations.
This study demonstrates a causal association between ALOX5 and IPF, partially mediated by gut microbiota, suggesting that combining leukotriene pathway inhibition with microbiota-targeted interventions may be a viable IPF strategy.
 
 
 
 
 
No
No
https://storage.unitedwebnetwork.com/files/1285/1221128-37089-a_381231.jpg
JPG or JPEG or PNG format ONLY
Idiopathic pulmonary fibrosis; drug target Mendelian randomization; ALOX5; gut microbiota
maximum 3 keywords and no abbreviations, separated by commas
We thank all GWAS participants and investigators for publicly making the summary statistics data available.
253